Markets:

Overview

News

Currencies

International

Treasuries

Rapport Therapeutics, Inc. - Common Stock (NQ:RAPP)

29.44 +0.01 (+0.03%)

Streaming Delayed Price Updated: 11:11 AM EST, Nov 28, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Rapport Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >

Rapport Therapeutics to Present New Phase 2a Data Analysis Further Characterizing RAP-219 in Focal Onset Seizures at 2025 American Epilepsy Society Annual Meeting

November 25, 2025

New analysis examines RAP-219’s effect during the first month of treatment and consistency of efficacy over the treatment period, effectiveness across baseline disease severities, and impact on seizure...

From Rapport Therapeutics, Inc.

Via GlobeNewswire

This Extreme Networks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗

November 19, 2025

Via Benzinga

Biotech Sector Soars: Promising Drug Trials Ignite Investor Confidence and Spark Market Rally

November 07, 2025

The biotech sector is currently experiencing a robust rally, a significant turnaround from a period of subdued performance. This resurgence is primarily fueled by a wave of promising drug trial results...

Via MarketMinute

Topics Artificial Intelligence Intellectual Property

Rapport Therapeutics Stock Rockets 204% Pre-Market To Head Toward All-Time Highs – Here’s What Happened ↗

September 08, 2025

Via Stocktwits

Rapport Therapeutics Inc (NASDAQ:RAPP) Reports Q3 2025 Earnings Beat and Positive Phase 2a Seizure Data ↗

November 06, 2025

Rapport Therapeutics beats Q3 earnings estimates, reports strong Phase 2a data for its lead drug candidate RAP-219, and has cash into 2029.

Via Chartmill

Topics Earnings

Rapport Therapeutics Reports Third Quarter 2025 Financials and Provides Business Update

November 06, 2025

From Rapport Therapeutics, Inc.

Via GlobeNewswire

Rapport Therapeutics to Participate in Upcoming Investor Conferences

November 05, 2025

From Rapport Therapeutics, Inc.

Via GlobeNewswire

Rapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

September 11, 2025

From Rapport Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

September 10, 2025

Via Benzinga

Rapport Announces Pricing of Public Offering of Common Stock

September 09, 2025

From Rapport Therapeutics, Inc.

Via GlobeNewswire

Let's take a look at the stocks that are in motion in today's session. ↗

September 09, 2025

Looking for insights into the US markets one hour before the close of the markets on Tuesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

Rapport Announces Proposed Public Offering of Common Stock

September 08, 2025

From Rapport Therapeutics, Inc.

Via GlobeNewswire

Top movers analysis one hour before the close of the markets on 2025-09-08: top gainers and losers in today's session. ↗

September 08, 2025

Let's have a look at what is happening on the US markets one hour before the close of the markets on Monday. Below you can find the top gainers and losers in today's session.

Via Chartmill

12 Health Care Stocks Moving In Monday's Intraday Session ↗

September 08, 2025

Via Benzinga

Top stock movements in today's session. ↗

September 08, 2025

Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top gainers and losers in today's session.

Via Chartmill

Gold Moves Higher; Robinhood Shares Jump ↗

September 08, 2025

Via Benzinga

Rapport Therapeutics, Planet Labs, QuantumScape, EchoStar And Other Big Stocks Moving Higher On Monday ↗

September 08, 2025

Via Benzinga

Nasdaq Surges 150 Points; Planet Labs Shares Jump After Q2 Results ↗

September 08, 2025

Via Benzinga

Rapport Catapults Almost 200% After Succeeding In Hard-To-Treat Seizures ↗

September 08, 2025

The company is working on a treatment for a form of epilepsy that tends to be difficult to control.

Via Investor's Business Daily

Rapport Reports Promising Epilepsy Study Outcomes, Plans Phase 3 Trials Next Year ↗

September 08, 2025

Rapport Therapeutics' RAP-219 cut seizures significantly in a Phase 2a trial, with strong results and a favorable safety profile driving next steps.

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

September 08, 2025

Via Benzinga

Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures

September 08, 2025

From Rapport Therapeutics, Inc.

Via GlobeNewswire

Why Robinhood Shares Are Trading Higher By Over 7%; Here Are 20 Stocks Moving Premarket ↗

September 08, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

September 05, 2025

Via Benzinga

Friday's after hours session: top gainers and losers ↗

September 05, 2025

After the conclusion of the US market's regular session on Friday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.

Via Chartmill

Rapport Therapeutics to Announce Topline Results for RAP-219 Phase 2a Trial in Focal Onset Seizures on Monday, September 8, 2025

September 05, 2025

From Rapport Therapeutics, Inc.

Via GlobeNewswire

Phibro Animal Health, Pure Storage, Snowflake, Build-A-Bear Workshop And Other Big Stocks Moving Higher On Thursday ↗

August 28, 2025

Via Benzinga

Rapport (RAPP) Q2 Net Loss Widens 47% ↗

August 07, 2025

Via The Motley Fool

Rapport Therapeutics Inc (NASDAQ:RAPP) Reports Narrower-Than-Expected Q2 2025 Loss Amid Clinical Progress ↗

August 07, 2025

Rapport Therapeutics reports Q2 2025 net loss of $26.7M ($0.75/share), beating estimates. Focus remains on Phase 2a trial for RAP-219 in epilepsy, with results expected in September. Cash reserves...

Via Chartmill

Rapport Therapeutics Reports Second Quarter 2025 Financials and Provides Business Update

August 07, 2025

From Rapport Therapeutics, Inc.

Via GlobeNewswire

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.